Flushing port with huber needle
Abstract:
Background: The totally implanted vascular access device (TIVAD) is commonly used in patients with malignant tumors requiring chemotherapy or long-term intravenous infusion and those with difficulty placing peripheral venous catheters. It could also be used to draw blood in pediatric patients. Thus, how to maintain the patency and longevity of TIVAD is always emphasized.
Methods: In this prospective study, TIVAD was randomly infused in patients under 18 years with three different concentrations of heparinized solutions: 10 mL with 100 U/ mL heparin, 20 mL with 10 U/mL heparin, and 30 mL with 10 U/mL heparin.
Results: A total of 81 patients (46 males and 35 females) were enrolled in this study from Aug. 2, 2013, to Feb. 1, 2017. The mean age of those who received TIVAD implantation was 7.2 ± 5.3 years, and the mean duration of using TIVAD was 1027.6 ± 369.1 days. Patients without catheter occlusion events experienced significantly shorter hospitalizations, fewer admissions, and fewer punctures than those with catheter occlusion events (p < 0.05). The administration and frequency of blood transfusions, history of bacteremia, and medication history did not increase the risk of catheter occlusion, but puncture frequency increased this risk. In patients with catheter occlusion events (38/81, 46.9%), catheter patency was restored after instillation of urokinase solution.
Conclusion: In this study, the risk of TIVAD catheter occlusion was only related to puncture frequency regardless of the heparin flush composition or patient characteristics. A high puncture frequency of TIVAD during the 3.5-year study period significantly increased the risk of catheter occlusion. Besides, flushing and locking solutions for TIVAD using heparin at 10 U/mL was effective as using heparin at 100 U/mL regardless of the flushing volume of 10, 20 or 30 mL.
Reference:
Hsieh HC, Hung SC, Huang SY, Huang FL, Chou CM. A prospective, randomized study assessing different modalities for flushing totally implanted vascular access device in children with malignancy. J Chin Med Assoc. 2021 Aug 18. doi: 10.1097/JCMA.0000000000000601. Epub ahead of print. PMID: 34407037.